Insider Selling: Jounce Therapeutics Inc (JNCE) CEO Sells 16,334 Shares of Stock
Jounce Therapeutics Inc (NASDAQ:JNCE) CEO Richard /Ca/ Murray sold 16,334 shares of Jounce Therapeutics stock in a transaction on Thursday, March 8th. The stock was sold at an average price of $25.10, for a total value of $409,983.40. Following the completion of the sale, the chief executive officer now directly owns 16,334 shares of the company’s stock, valued at approximately $409,983.40. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.
Richard /Ca/ Murray also recently made the following trade(s):
- On Monday, March 5th, Richard /Ca/ Murray sold 16,334 shares of Jounce Therapeutics stock. The stock was sold at an average price of $21.43, for a total value of $350,037.62.
Shares of Jounce Therapeutics Inc (NASDAQ:JNCE) opened at $27.32 on Wednesday. Jounce Therapeutics Inc has a fifty-two week low of $11.05 and a fifty-two week high of $29.29. The stock has a market capitalization of $808.49, a PE ratio of -49.67 and a beta of 8.00.
A number of large investors have recently added to or reduced their stakes in JNCE. BlackRock Inc. grew its holdings in Jounce Therapeutics by 60.1% during the fourth quarter. BlackRock Inc. now owns 1,161,840 shares of the company’s stock valued at $14,812,000 after purchasing an additional 436,114 shares during the period. Fosun International Ltd grew its holdings in Jounce Therapeutics by 208.8% during the third quarter. Fosun International Ltd now owns 285,960 shares of the company’s stock valued at $4,455,000 after purchasing an additional 193,350 shares during the period. Millennium Management LLC grew its holdings in Jounce Therapeutics by 310.4% during the fourth quarter. Millennium Management LLC now owns 246,021 shares of the company’s stock valued at $3,137,000 after purchasing an additional 186,068 shares during the period. Brown Advisory Inc. grew its holdings in Jounce Therapeutics by 55.9% during the third quarter. Brown Advisory Inc. now owns 475,719 shares of the company’s stock valued at $7,411,000 after purchasing an additional 170,661 shares during the period. Finally, Vanguard Group Inc. grew its holdings in Jounce Therapeutics by 123.8% during the second quarter. Vanguard Group Inc. now owns 255,060 shares of the company’s stock valued at $3,578,000 after purchasing an additional 141,096 shares during the period. 90.81% of the stock is owned by institutional investors and hedge funds.
Several analysts have issued reports on JNCE shares. Zacks Investment Research raised Jounce Therapeutics from a “sell” rating to a “hold” rating in a report on Wednesday, November 15th. Robert W. Baird set a $35.00 price target on Jounce Therapeutics and gave the company a “buy” rating in a report on Thursday, March 8th.
COPYRIGHT VIOLATION WARNING: “Insider Selling: Jounce Therapeutics Inc (JNCE) CEO Sells 16,334 Shares of Stock” was published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this report on another publication, it was illegally stolen and reposted in violation of U.S. & international trademark and copyright law. The correct version of this report can be read at https://www.thecerbatgem.com/2018/03/14/insider-selling-jounce-therapeutics-inc-jnce-ceo-sells-16334-shares-of-stock.html.
About Jounce Therapeutics
Jounce Therapeutics, Inc is a clinical stage immunotherapy company. The Company is engaged in transforming the treatment of cancer by developing therapies that enable the immune system to attack tumors and provide long lasting benefits to patients. Through the use of its Translational Science Platform, Jounce first focuses on specific cell types within tumors to prioritize targets, and then identifies related biomarkers designed to match the right therapy to the right patient.
Receive News & Ratings for Jounce Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jounce Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.